Breaking

Nigerian university sparks outrage as staff check whether female students are wearing bras before exams
Iran watches decades-old red lines vanish from view, but Trump still faces a huge risk
‘It feels like a missile is following me’: Iranians say daily life filled with fear and distrust
Chinese student who drugged and raped 10 women in UK and China sentenced to life in prison
70 rhinos reared at controversial captive breeding farm set free in Rwanda
Western diplomats welcome two-week breather to ‘explore what is possible’ on Iran’s nuclear program
Xi and Putin present united front over Israel-Iran crisis, in veiled message to Trump
Two men convicted in Pennsylvania mayoral race election fraud case hit with harsher sentences than expected

Business
Politics
World
Investing
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Crypto Market Recap: Institutional Investments, Stablecoin News and ETF Activity

Cygnus raises $18.3m to accelerate resource growth and mining studies

Allied Critical Metals

Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (53)
- Investing (228)
- Politics (267)
- World (254)

Disclaimer: TimeFinances.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 TimeFinances.com | All Rights Reserved

Top

Business
Politics
World
Investing

Type above and press Enter to search. Press Esc to cancel.